CORT Quote, Financials, Valuation and Earnings

Collegium Pharmaceutical has a net margin of 13.07% compared to Corcept Therapeutics's net margin of 1.36%. Corcept Therapeutics's return on equity of 21.3% beat Collegium Pharmaceutical's return on equity of 19.31%.

Corcept Therapeutics has a consensus price target of $138.25, signalling upside risk potential of 78.04%. On the other hand Collegium Pharmaceutical has an analysts' consensus of $41.25 which suggests that it could grow by 42.68%. Given that Corcept Therapeutics has higher upside potential than Collegium Pharmaceutical, analysts believe Corcept Therapeutics is more attractive than Collegium Pharmaceutical.

Corcept Therapeutics has a beta of 0.215, which suggesting that the stock is 78.473% less volatile than S&P 500. In comparison Collegium Pharmaceutical has a beta of 0.629, suggesting its less volatile than the S&P 500 by 37.082%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Collegium Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Collegium Pharmaceutical pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $157.2M, which are smaller than Collegium Pharmaceutical quarterly revenues of $177.8M. Corcept Therapeutics's net income of $20.5M is higher than Collegium Pharmaceutical's net income of $2.4M. Notably, Corcept Therapeutics's price-to-earnings ratio is 66.94x while Collegium Pharmaceutical's PE ratio is 23.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 13.14x versus 1.67x for Collegium Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 13.07% compared to Corcept Therapeutics's net margin of -907.48%. Corcept Therapeutics's return on equity of 21.3% beat Moderna's return on equity of -29.23%.

Corcept Therapeutics has a consensus price target of $138.25, signalling upside risk potential of 78.04%. On the other hand Moderna has an analysts' consensus of $47.70 which suggests that it could grow by 83.09%. Given that Moderna has higher upside potential than Corcept Therapeutics, analysts believe Moderna is more attractive than Corcept Therapeutics.

Corcept Therapeutics has a beta of 0.215, which suggesting that the stock is 78.473% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $157.2M, which are larger than Moderna quarterly revenues of $107M. Corcept Therapeutics's net income of $20.5M is higher than Moderna's net income of -$971M. Notably, Corcept Therapeutics's price-to-earnings ratio is 66.94x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 13.14x versus 3.23x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 13.07% compared to Corcept Therapeutics's net margin of 21.63%. Corcept Therapeutics's return on equity of 21.3% beat Pfizer's return on equity of 8.72%.

Corcept Therapeutics has a consensus price target of $138.25, signalling upside risk potential of 78.04%. On the other hand Pfizer has an analysts' consensus of $29.37 which suggests that it could grow by 26.7%. Given that Corcept Therapeutics has higher upside potential than Pfizer, analysts believe Corcept Therapeutics is more attractive than Pfizer.

Corcept Therapeutics has a beta of 0.215, which suggesting that the stock is 78.473% less volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.33% to investors and pays a quarterly dividend of $0.43 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $157.2M, which are smaller than Pfizer quarterly revenues of $13.7B. Corcept Therapeutics's net income of $20.5M is lower than Pfizer's net income of $3B. Notably, Corcept Therapeutics's price-to-earnings ratio is 66.94x while Pfizer's PE ratio is 16.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 13.14x versus 2.12x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals has a net margin of 13.07% compared to Corcept Therapeutics's net margin of -7.89%. Corcept Therapeutics's return on equity of 21.3% beat Supernus Pharmaceuticals's return on equity of 6.24%.

Corcept Therapeutics has a consensus price target of $138.25, signalling upside risk potential of 78.04%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $38.80 which suggests that it could grow by 20.68%. Given that Corcept Therapeutics has higher upside potential than Supernus Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Supernus Pharmaceuticals.

Corcept Therapeutics has a beta of 0.215, which suggesting that the stock is 78.473% less volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.736, suggesting its less volatile than the S&P 500 by 26.408%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $157.2M, which are larger than Supernus Pharmaceuticals quarterly revenues of $149.8M. Corcept Therapeutics's net income of $20.5M is higher than Supernus Pharmaceuticals's net income of -$11.8M. Notably, Corcept Therapeutics's price-to-earnings ratio is 66.94x while Supernus Pharmaceuticals's PE ratio is 28.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 13.14x versus 2.70x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.